The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 123, Issue 9, 2016, Pages 1441-1452

  Al Rubaie, Z T A ^a   Askie, L M ^b   Ray, J G ^c   Hudson, H M ^b,d   Lord, S J ^a,b  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

Aspirin; pre eclampsia; risk factors; risk prediction models; systematic review; validation

Indexed keywords

CLINICAL FEATURE; HUMAN; HYPERTENSION; MATERNAL WELFARE; MEDICAL DECISION MAKING; MEDICAL HISTORY; MEDICAL PARAMETERS; PRACTICE GUIDELINE; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; RACE; REVIEW; RISK ASSESSMENT; RISK PREDICTION MODEL; SYSTEMATIC REVIEW;

EID: 84979017484     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14029     Document Type: Review

References (53)

1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74.
2. National High Blood Pressure Education Program. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1–22.
3. Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS ONE 2014;9:e91198.
4. Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, et al. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open 2011;1:e000101.
5. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014;2:e323–33.
6. United Nations. The Millennium Development Goals: Report 2015. New York: United Nations; 2015.
7. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8.
8. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi A, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6.
9. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116(2 Pt 1):402–14.
10. National Institute for Health and Care Excellence. NICE Quality Standard 35. Hypertension in Pregnancy. London: NICE, 2013.
11. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280–6.
12. Goetzinger KR, Tuuli MG, Cahill AG, Macones GA, Odibo AO. Development and validation of a risk factor scoring system for first-trimester prediction of preeclampsia. Am J Perinatol 2014;31:1049–56.
13. Caradeux J, Serra R, Nien JK, Perez-Sepulveda A, Schepeler M, Guerra F, et al. First trimester prediction of early onset preeclampsia using demographic, clinical, and sonographic data: a cohort study. Prenatal Diagn 2013;33:732–6.
14. Direkvand-Moghadam A, Khosravi A, Sayehmiri K. Predictive factors for preeclampsia in pregnant women: a receiver operation character approach. Arch Med Sci 2013;9:684–9.
15. Keikkala E, Vuorela P, Laivuori H, Romppanen J, Heinonen S, Stenman UH. First trimester hyperglycosylated human chorionic gonadotrophin in serum—a marker of early-onset preeclampsia. Placenta 2013;34:1059–65.
16. Kuc S, Koster MP, Franx A, Schielen PC, Visser GH. Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia. PLoS ONE 2013;8:e63546.
17. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepulveda-Martinez A, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013;41:538–44.
18. Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013;208:203.e1–10.
19. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, et al. First trimester maternal serum PIGF, free beta-hCG, PAPP-A, PP–13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta 2012;33:495–501.
20. Kuijk SMJV, Nijdam ME, Janssen KJM, Sep SJS, Peeters LL, Delahaije DHJ, et al. A model for preconceptional prediction of recurrent early-onset preeclampsia: derivation and internal validation. Reprod Sci 2011;18:1154–9.
21. North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (Clinical Research Edn) 2011;342:d1875–d.
22. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 2011;32:598–602.
23. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO. Predicting the risk of pre-eclampsia between 11 and 13 weeks’ gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenatal Diagn 2010;30:1138–42.
24. Poon LCY, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: Combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenatal Diagn 2010;30:216–23.
25. Emonts P, Seaksan S, Seidel L, Thoumsin H, Gaspard U, Albert A, et al. Prediction of maternal predisposition to preeclampsia. Hypertens Pregnancy 2008;27:237–45.
26. Poon LCY, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11–13 weeks. Hypertens Pregnancy 2011;30:93–107.
27. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH. Maternal plasma soluble endoglin at 11–13 weeks’ gestation in pre-eclampsia. Ultrasound Obstet Gynecol 2010;35:680–7.
28. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010;35:662–70.
29. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010;24:104–10.
30. Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH. First-trimester maternal serum tumor necrosis factor receptor–1 and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:135–41.
31. Poon LCY, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11–13 weeks. Ultrasound Obstet Gynecol 2009;34:497–502.
32. Poon LCY, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11–13 weeks. Ultrasound Obstet Gynecol 2009;34:142–8.
33. Poon LCY, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenatal Diagn 2009c;29:553–9.
34. Poon LCY, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:812–8.
35. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23–33.
36. +6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732–9.
37. De Paco C, Kametas N, Rencoret G, Strobl I, Nicolaides KH. Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small for gestational age. Obstet Gynecol 2008;111(2 Pt 1):292–300.
38. +6 weeks in the prediction of preeclampsia. Hypertension 2008;51:1027–33.
39. +6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742–9.
40. Myers JE, Kenny LC, McCowan LME, Chan EHY, Dekker GA, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013;120:1215–23.
41. Park FJ, Leung CHY, Poon LCY, Williams PF, Rothwell SJ, Hyett JA. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aus N Z J Obstet Gynaecol 2013;53:532–9.
42. Farina A, Rapacchia G, Freni Sterrantino A, Pula G, Morano D, Rizzo N. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenatal Diagn 2011;31:1147–52.
43. Herraiz I, Arbues J, Camano I, Gomez-Montes E, Graneras A, Galindo A. Application of a first-trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenatal Diagn 2009;29:1123–9.
44. Steyerberg EW, Harrell FE Jr. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol 2016;69:245–7.
45. Brunelli VB, Prefumo F. Quality of first trimester risk prediction models for pre-eclampsia: a systematic review. BJOG 2015;122:904–14.
46. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565.
47. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenatal Diagn 2015;35:183–91.
48. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG. Prediction of preeclampsia utilizing the first trimester screening examination. Am J Obstet Gynecol 2014;211:514.e1–7.
49. Skrastad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen K. Risk assessment for preeclampsia in nulliparous women at 11–13 weeks’ gestational age: prospective evaluation of two algorithms. BJOG 2015;122:1781–8.
50. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213:62.e1–10.
51. LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:819–26.
52. Bartsch E, Park AL, Kingdom JC, Ray JG. Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost. PLoS ONE 2015;10:e0116296.
53. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1–73.